Technology | 2016.06.07
Massachusetts General Hospital Enters Into a Technology Alliance Partnership with IntelliCyt for the Development of CRISPR Functional Screening Applications
CRISPR/Cas9 genome editing technology holds great promise for identifying therapeutic drugs targets. Through high-throughput CRISPR functional screening, improving drug selection is expected to ultimately result in better, safer, more efficacious drugs.
(PRWeb June 06, 2016)
Read the full story at http://www.prweb.com/releases/2016/06/prweb13461416.htm
For more information, please visit
http://www.prweb.com/releases/2016/06/prweb13461416.htm
